A question of duration: Do patients with early-stage breast cancer need more than five years of Adjuvant endocrine therapy?

Clinical Breast Cancer

Volumn 9, Issue SUPPL.1, 2009, Pages

  Burdette Radoux, Susan ^a   Muss, Hyman B ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Aromatase inhibitors; Arthralgia; Exemestane; Letrozole; Menopause; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALOPECIA; ANOREXIA; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; HOT FLUSH; HUMAN; MYALGIA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; POSTMENOPAUSE; PREMENOPAUSE; RISK REDUCTION; SHORT SURVEY; TREATMENT DURATION; VAGINA BLEEDING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; REVIEW; TIME;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 70249095048     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.s.004     Document Type: Article

References (24)

1. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
2. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [published erratum in: JAMA 2006;295:2356].
3. JAMA 2006;295:1658-67.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
5. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
6. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996;88:1828-33.
7. Stewart HJ, Prescott RJ, Forrest APM. Scottish Adjuvant Tamoxifen Trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-62.
8. Peto R, Davies C. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter) : international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11, 500 women - preliminary results. Presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 48. Available at: http://www.abstracts2view.com/sabcs07/view.php?nu=SABCS07L-1167. Accessed: March 26, 2009.
9. Gray RG, Rea DW, Handley K, et al. aTTom (adjuvant Tamoxifen-To offer more?) : randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6, 934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-preliminary results. J Clin Oncol 2008;26(suppl) :10s (abstract 513).
10. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
11. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
12. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup trial MA.17. J Clin Oncol 2008;26:1956-64.
13. Adjuvant! Online [Web site]. Available at: http://adjuvantonline.com. Accessed: June 8, 2009.
14. Mamounas E P, Jeong J-H, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008;26:1965-71.
15. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a [published erratum in: J Natl Cancer Inst 2008;100:226].
16. J Natl Cancer Inst 2007;99:1845-53.
17. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen [published erratum in: J Clin Oncol 2008;26:3659].
18. J Clin Oncol 2008;26:1948-55.
19. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-40.
20. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910-7.
21. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:4261-71.
22. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42.
23. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-36.
24. Greenspan SL, Brufsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644-52.